Retailers sell CGMs for $55

Continuous glucose monitors used to be medical hardware you got through a clinician, an insurer, and usually a lot of paperwork. That was the bottleneck. The sensor itself was useful, but access was the real product problem. Now that barrier is breaking: Dexcom’s Stelo and Abbott’s Lingo and Libre Rio are cleared for sale without a prescription in the U.S., and the effective entry price has fallen to roughly $50 to $55 per sensor instead of a much bigger, clinic-mediated commitment. ### What exactly is selling for about $55? The cleanest example is Dexcom Stelo. Dexcom’s direct store lists a one-time purchase at $99 for two biosensors, each lasting up to 15 days. That works out to about $49.50 per sensor, and with retailer markups, discounts, or smaller-unit framing, social posts calling this a “$55 CGM” are basically pointing at the right order of magnitude. Amazon is also listing Stelo as a consumer product, which matters because it makes the device feel like normal retail inventory, not specialty medical equipment. (fda.gov) ### Which products are actually OTC now? There are three real OTC names to know. Dexcom Stelo was the first over-the-counter CGM cleared by the FDA in March 2024. Abbott followed in June 2024 with two products: Lingo, aimed at general wellness and metabolic health, and Libre Rio, aimed at adults with type 2 diabetes who do not use insulin. That split is important — these are not all the same product wearing different branding. One is pitched as consumer coaching, one as diabetes self-management, and one sits in between. (stelo.com) ### Why is this a bigger deal than a cheaper gadget? Because the old friction was not just price. It was gatekeeping. Prescription status meant doctor visits, prior authorization fights, coverage uncertainty, and a general sense that CGMs were only for more advanced diabetes care. OTC clearance changes the category. Dexcom explicitly markets Stelo as “no prescription,” and Abbott says Lingo is available to consumers without one. That turns CGMs into something closer to buying a blood pressure cuff or smart scale — still specialized, but no longer institutionally blocked. (fda.gov) ### Who are these sensors for? Not everyone. Stelo is for adults 18 and older who do not use insulin, and Dexcom says not to use it if you have problematic hypoglycemia, are on insulin, or are on dialysis. Libre Rio is also for adults 18 and older with type 2 diabetes who do not use insulin. Lingo is the broadest consumer play — Abbott frames it as a wellness product for people who want to understand how food and activity affect glucose. So yes, access widened, but the labeling still draws hard lines around riskier users. (provider.dexcom.com) ### What do you actually get for the money? A small arm-worn sensor, a phone app, and a stream of glucose data over days or weeks. Stelo offers up to 15 days per sensor with pattern and spike tracking. Lingo lasts up to 14 days and leans hard into coaching and habit formation. The point is not a one-off glucose check. It is seeing how sleep, exercise, meal timing, and specific foods move your glucose over time. That can be genuinely useful — but only if the app helps translate the graph into something actionable. (stelo.com) ### So what’s the catch? More data is not the same thing as better decisions. The FDA clearance for Stelo specifically excludes people who need alerts for dangerous lows, and Dexcom tells users not to make medication changes without talking to a healthcare provider. Abbott makes a similar distinction by separating wellness users from diabetes users. Basically, OTC access solves distribution faster than it solves interpretation. A person can now buy a sensor in minutes, but understanding whether a spike matters still takes context. (stelo.com) ### Why now? The technology was already mature. What changed was the regulatory wrapper and the go-to-market plan. FDA clearance in 2024 opened the door, and by 2026 these products are showing up in ordinary online retail channels. That is why the story feels sudden now even though the approvals are older — the category is finally behaving like consumer electronics instead of durable medical equipment. (fda.gov) ### Bottom line? The real news is not that a CGM can cost about $55. It is that CGMs are becoming buyable, tryable, and normal. Price made the headline, but access is the deeper shift. (stelo.com) (fda.gov)